Axim Biotechnologies Inc. (AXIM)

Overview

AXIM Biotechnologies, Inc., headquartered in San Diego, California, is a biotechnology company focused on developing and commercializing various diagnostic healthcare solutions. Founded in 2010 and initially named Axim International Inc., the company underwent a rebranding to AXIM Biotechnologies, Inc. in July 2014. The company's mission encompasses a broad spectrum of diagnostic healthcare areas, including SARS-CoV-2, eye health, and the detection and monitoring of various diseases, highlighting its dedication to addressing urgent and widespread health concerns.

Products and Services

• Dry Eye Disease Tests

  AXIM Biotechnologies is pioneering in the development of diagnostic tests for dry eye diseases. These tests aim to provide accurate and early detection, improving the management and treatment of this common yet often undiagnosed condition.

• SARS-CoV-2 Neutralizing Antibody Tests

  In response to the global COVID-19 pandemic, the company has developed neutralizing antibody tests for SARS-CoV-2. These tests are designed to detect the presence of antibodies that can neutralize the virus, indicating a level of immunity and potentially playing a crucial role in managing the pandemic.

• Fentanyl Neutralizing Antibody Tests

  With the rise of opioid overdoses, AXIM Biotechnologies focuses on creating tests for the detection of fentanyl neutralizing antibodies. This innovation is key in the fight against opioid overdose deaths, offering potential for early detection and intervention.

• Novel Diagnostics for Early Cancer Detection, Response to Treatment, and Recurrence Monitoring

  AXIM is developing a range of novel diagnostics aimed at revolutionizing cancer care. These advanced diagnostics facilitate early detection, monitor patient response to treatments, and help in keeping track of disease recurrence, thereby contributing to more personalized and effective cancer management strategies.